NasdaqCM - Nasdaq Real Time Price USD

Avalon GloboCare Corp. (ALBT)

3.7800

-0.0500

(-1.31%)

At close: May 21 at 4:00:00 PM EDT

Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement

FREEHOLD, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, and YOOV Group Holding Limited (“YOOV”), a provider of highly advanced artificial intelligence (“AI”) automation solutions, jointly announced the filing with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form S-4 in connection with the pro

GlobeNewswire 22 days ago

ALBT
-1.31%
Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAir

Avalon’s KetoAir™ breathalyzer used to maintain progress for law enforcement to establish and meet their BrAce goals during the ongoing BrAce 4 Impact ChallengeFREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of SpecialtyHealth, Inc. (“SpecialtyHealth”) — co-founded by Dr. EJ Greenwald, the pion

GlobeNewswire last month

ALBT
-1.31%
Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

FREEHOLD, N.J., April 10, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration (CNIPA). The patent, entitled “Artificial Immunosurveillance Chimeric Antigen Receptor an

GlobeNewswire last month

ALBT
-1.31%
Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series

KetoAir Now In Stock at All Three Pounds Transformation Clinics in ConnecticutFREEHOLD, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced that it has partnered with Pounds Transformation Clinics, led by Dr. Charles Cavo, a member of the Zero to Keto Affiliate Marketing Program, to launch the “BrAce 4 Impact Challenge S

GlobeNewswire last month

ALBT
-1.31%
Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million with Net Income of $3.4 Million for Calendar Year 2024, Versus Unaudited Revenue of $28.7 Million with Net Loss of $2.4 Million for Calendar Year 2023 Upon Consummation of the Merger, Pending Nasdaq Approval, the New Combined Company is Expected to Trade Under the Nasdaq Symbol “YOOV” FREEHOLD, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a commer

GlobeNewswire 2 months ago

ALBT
-1.31%
Fusion Fuel Appoints Luisa Ingargiola to Board of Directors

DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (Nasdaq: HTOO) ("Fusion Fuel" or the "Company"), a leading provider of gas and hydrogen energy solutions, today announced the appointment of Luisa Ingargiola to its Board of Directors, effective February 24, 2025. Ms. Ingargiola will serve as chairperson of the Audit Committee, replacing Rune Magnus Lundetrae, who will remain a member of the Board. She will also serve as a member of the Nominating Committee, Audit Committe

GlobeNewswire 2 months ago

BICX

ALBT
-1.31%

HTOO
Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China

FREEHOLD, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance from the China National Intellectual Property Administration (CNIPA) for its patent application AVAR1901CN. This patent, co-developed with Hong Kong-based Arbele Limited, marks a milestone in the advancement of chimeric antigen receptor (CAR)-based th

GlobeNewswire 2 months ago

ALBT
-1.31%
Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements

FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on November 19, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550(a)(2). David Jin, M.D., Ph.D., CEO of Avalon GloboCare, stated, “Regaining com

GlobeNewswire 5 months ago

ALBT
-1.31%
Avalon GloboCare Third Quarter 2024 Earnings: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Avalon GloboCare ( NASDAQ:ALBT ) Third Quarter 2024 Results Key Financial Results Net loss: US$1.68m (loss widened by...

Simply Wall St. 6 months ago

ALBT
-1.31%
Top Premarket Decliners

Top Premarket Decliners

PREMIUM
MT Newswires 6 months ago

ALBT
-1.31%
Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales

Dr. Cavo’s expertise will advance the marketing and business development of KetoAir™, a handheld breathalyzer for ketogenic healthFREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transfo

GlobeNewswire 6 months ago

ALBT
-1.31%
Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannab

GlobeNewswire 6 months ago

ALBT
-1.31%
EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer

On Friday, Avalon GloboCare Corp. (NASDAQ:ALBT) entered into a memorandum of understanding (MOU) with Qi Diagnostics Limited, a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. The MOU provides Avalon with a 120-day exclusivity period during which Avalon intends to negotiate with Qi Diagnostics and enter into a definitive agreement regarding the pro

Benzinga 6 months ago

ALBT
-1.31%
Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it will effect a 1-for-15 reverse split (“reverse split”) of its common shares that will become effective on October 28, 2024. The Company expects that the reverse stock split will allow the Company to regain compliance with the $1.00 minimum bid price requirement of the Nasdaq Capital Ma

GlobeNewswire 6 months ago

ALBT
-1.31%
Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device

KetoAir and its related accessories will be available for purchase at the conferenceFREEHOLD, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, today announced its participation as an event sponsor at the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, at the Galt House Hotel in Louisville, KY. Avalon will use the event to showcase the KetoAir™ breat

GlobeNewswire 7 months ago

ALBT
-1.31%
Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device

Device is Approved for Reimbursement by Medicare and is Supported by Several Private Insurance ProvidersFREEHOLD, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has begun manufacturing the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. L

GlobeNewswire 9 months ago

ALBT
-1.31%
EXCLUSIVE: Avalon's Lab Services MSO Poised To Commercialize FDA-Registered External Male Catheter Device

On Wednesday, Avalon GloboCare Corp. (NASDAQ:ALBT) announced that Laboratory Services MSO, LLC has begun manufacturing the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. Avalon owns a 40% interest in Laboratory Services MSO. Laboratory Services MSO plans to launch its sales of the GeeWhiz External Condom Catheter in the third quarter of 2024. According to Grand View Research, the global male urinary incontinence market size was valued at $6.37

Benzinga 9 months ago

ALBT
-1.31%
Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Direct-To-Consumer, Non-Invasive Kit is Available in the U.S. for Convenient At-Home Sample CollectionFREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependen

GlobeNewswire 9 months ago

ALBT
-1.31%
7 F-Rated Penny Stocks to Avoid This June

There are risks associated with any investment – there’s no such thing as a surefire investment, although tools like the Portfolio Grader can make your life easier when looking for stocks to buy and those to avoid. One of the riskiest investments are in F-rated penny stocks, and those should be avoided at all costs when you’re considering your portfolio. Penny stocks are low-priced securities, but they really don’t cost a penny. Instead, they are shares of stocks that are priced at less than $5

InvestorPlace 10 months ago

TNXP

TSLA

KITTW
Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

FREEHOLD, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today provided an update on the launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference that was held on May 31 to June 2, 2024 in Austin, Texas. “We're excited to report the successful launch of KetoAir™ breathalyze

GlobeNewswire 10 months ago

ALBT
-1.31%

Performance Overview

Return	ALBT	S&P 500 (^GSPC)
YTD	+15.95%	-0.63%
1-Year	-13.10%	+9.83%
3-Year	-94.55%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Avalon GloboCare Corp. (ALBT)

Avalon GloboCare Advances Proposed Merger with YOOV with Filing of Registration Statement

Avalon GloboCare Partners with SpecialtyHealth, Inc. to Power Police Chiefs’ Fitness Challenge with KetoAir

Avalon GloboCare Announces Issuance of Patent for Novel CAR-T and CAR-NK Cell Technology in China

Avalon GloboCare Partners with Pounds Transformation Clinics to Unveil the KetoAir BrAce 4 Impact Challenge Series

Avalon GloboCare and YOOV, a Leading Business AI Automation Solutions Provider, Enter into Merger Agreement

Fusion Fuel Appoints Luisa Ingargiola to Board of Directors

Avalon GloboCare Receives Notice of Allowance for Groundbreaking CAR-T and CAR-NK Cell Technology in China

Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements

Avalon GloboCare Third Quarter 2024 Earnings: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Top Premarket Decliners

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales

Avalon GloboCare and Qi Diagnostics Enter into Memorandum of Understanding for Proposed Co-Development of Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

EXCLUSIVE: Avalon GloboCare Inks MoU With Qi Diagnostics For Proposed Co-Development Of Real-Time Cannabis Breathalyzer

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Avalon GloboCare to Sponsor Keto Pa-LOU-za 2024 Conference and Showcase KetoAir Breathalyzer Device

Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device

EXCLUSIVE: Avalon's Lab Services MSO Poised To Commercialize FDA-Registered External Male Catheter Device

Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

7 F-Rated Penny Stocks to Avoid This June

Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Performance Overview